Abstract

Survival in Primary Myelofibrosis: A Population-based Analysis in the Netherlands

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Differences In Community and Academic Practice Patterns For Newly Diagnosed Myelodysplastic Syndromes (MDS) Patients In Minnesota: A Population Based Study
Michelle A Roesler ... Erica D Warlick
Blood | VOL. 122
Michelle A Roesler, et. al.Michelle A Roesler ... Erica D Warlick
15 Nov 2013
Platelet count is an IPSS‐independent risk factor predicting survival in refractory anaemia with ringed sideroblasts
David P Steensma ... Shanique R Palmer
British Journal of Haematology | VOL. 140
David P Steensma, et. al.David P Steensma ... Shanique R Palmer
31 Jan 2008
Validation of the Newly Proposed MD Anderson Prognostic Risk Model for Patients with Myelodysplastic Syndromes
Maria Corrales-Yepez ... Jeffrey E Lancet
Blood | VOL. 116
Maria Corrales-Yepez, et. al.Maria Corrales-Yepez ... Jeffrey E Lancet
19 Nov 2010
Validation of the Lower Risk MD Anderson Prognostic Scoring System for Patients with Myelodysplastic Syndromes
Ling Zhang ... Javier Pinilla-Ibarz
Blood | VOL. 120
Ling Zhang, et. al.Ling Zhang ... Javier Pinilla-Ibarz
16 Nov 2012
View more papers

More From: HemaSphere

Paper Title
Journal
Date
Author
An integrated classification of tumor suppressor IKZF1 inactivation and oncogenic activation in Philadelphia chromosome-like acute lymphoblastic leukemia.
Zicong Huang ... Hongsheng Zhou
HemaSphere | VOL. 8
Zicong Huang, et. al.Zicong Huang ... Hongsheng Zhou
01 May 2024
Interplay between α-thalassemia and β-hemoglobinopathies: Translating genotype-phenotype relationships into therapies.
Jim Vadolas ... George Grigoriadis
HemaSphere | VOL. 8
Jim Vadolas, et. al.Jim Vadolas ... George Grigoriadis
01 May 2024
Towarda more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS).
Fabio Efficace ... Amer M Zeidan
HemaSphere | VOL. 8
Fabio Efficace, et. al.Fabio Efficace ... Amer M Zeidan
01 May 2024
-
-
HemaSphere | VOL. 8
--
01 May 2024
View more papers